Nautilus Biotechnology Inc
NASDAQ:NAUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
US |
|
Tifico Fiber Indonesia Tbk PT
IDX:TFCO
|
ID |
|
Foryou Corp
SZSE:002906
|
CN |
|
Eventbrite Inc
NYSE:EB
|
US |
|
Sprouts Farmers Market Inc
NASDAQ:SFM
|
US |
|
CYNGN Inc
NASDAQ:CYN
|
US |
|
Bank of New York Mellon Corp
NYSE:BK
|
US |
Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
Expense Discipline: Nautilus cut total operating expenses by 23% in Q4 and 18% for the full year 2025, mainly through lower headcount and development spending.
Voyager Instrument Debut: The Voyager instrument was publicly unveiled at the US HUPO conference to strong positive feedback from the research community.
Early Access Launch: The Early Access Program for Iterative Mapping launched ahead of schedule, starting with the Tau proteoform assay and receiving encouraging initial customer response.
Pipeline Expansion: Nautilus announced a new $1.2 million MJFF-funded collaboration to develop an alpha-synuclein assay for Parkinson's, broadening its proteoform portfolio.
2026 Guidance: Operating expenses are expected to rise by 15–20% in 2026, with cash burn projected at $65–70 million as investments increase for commercial readiness.
Revenue Outlook: 2026 revenue will be modest, mainly from grants and early access services, with primary instrument sales and ramp-up expected in 2027.
